Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib
- 3 October 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 11 (11), 4199-4207
- https://doi.org/10.1021/mp500435s
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Tumor adaptation and resistance to RAF inhibitorsNature Medicine, 2013
- Advances in therapy for melanoma brain metastasesClinics in Dermatology, 2013
- Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted AgentsMolecular Cancer Therapeutics, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Insight into the Cooperation of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) at the Blood–Brain Barrier: A Case Study Examining Sorafenib Efflux ClearanceMolecular Pharmaceutics, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active EffluxJournal of Pharmacology and Experimental Therapeutics, 2010
- An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016): TABLE 1Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- Interaction of Imatinib Mesilate with Human P-GlycoproteinJournal of Pharmacology and Experimental Therapeutics, 2003
- Mutations of the BRAF gene in human cancerNature, 2002